

EP 0 682 038 A1



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 682 038 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art.
158(3) EPC

(21) Application number: 94904756.7

(61) Int. Cl. 6: C07H 17/08, //A61K31/71

(22) Date of filing: 24.01.94

(86) International application number:
PCT/JP94/00087

(87) International publication number:
WO 94/17088 (04.08.94 94/18)

(30) Priority: 26.01.93 JP 10351/93

(43) Date of publication of application:
15.11.95 Bulletin 95/46

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

(71) Applicant: TAISHO PHARMACEUTICAL CO.
LTD
24-1 Takata 3-chome
Toshima-ku
Tokyo 171 (JP)

(72) Inventor: MISAWA, Yoko
Taisho Pharm. Co., Ltd.
24-1, Takata 3-chome
Toshima-ku
Tokyo 171 (JP)
Inventor: ASAOKA, Toshifumi
Taisho Pharm. Co., Ltd.
24-1, Takata 3-chome
Toshima-ku

Tokyo 171 (JP)

Inventor: KASHIMURA, Masato
Taisho Pharm. Co., Ltd.
24-1, Takata 3-chome

Toshima-ku
Tokyo 171 (JP)
Inventor: MORIMOTO, Shigeo
Taisho Pharm. Co., Ltd.
24-1, Takata 3-chome


Toshima-ku
Tokyo 171 (JP)
Inventor: HATAYAMA, Katsuo
Taisho Pharm. Co., Ltd.
24-1, Takata 3-chome
Toshima-ku
Tokyo 171 (JP)

(74) Representative: Weisert, Annekäte, Dipl.-Ing.

Dr.-Ing. et al
Patentanwälte
Kraus Weisert & Partner
Thomas-Wimmer-Ring 15
D-80539 München (DE)

(54) 5-O-DESOSAMINYLERYTHRONOLIDE DERIVATIVE.

(57) A novel macrolide antibiotic having a potent antimicrobial activity, represented by general formula (1), which is produced by introducing a specified aryloxy or alkyloxy group into the 3-position of a 5-O-desosaminylerythronolide derivative, wherein Y represents oxygen-containing C₄-C₆ cycloalkyl, optionally substituted phenyl, glucopyranosyl, ribopyranosyl, benzyl or methyl; U represents hydrogen or acyl; Z represents oxygen or N-OR₁ wherein R₁ represents hydrogen, alkanoyl or optionally substituted benzyl; and A represents a group that forms an erythronolide which may form a cyclic carbonate group between the 11- and the 12-positions or a double bond between the 10- and 11-positions.



Technical Field

The present invention relates to novel derivatives of an antibacterial erythromycin, and more particularly relates to novel derivatives of 5-O-desosaminylerythronolide and pharmaceutically acceptable acid addition salts thereof.

Background of Art

Erythromycins are antibiotics clinically widely used as agents for treating infectious diseases caused by Gram-positive bacteria, some Gram-negative bacteria, mycoplasmas, etc. Many erythromycin derivatives have been prepared for the improvement of biological and/or pharmacological properties of erythromycins. Examples of prior art 5-O-desosaminylerythronolide derivative are 3-O-acyl-5-O-desosaminylerythronolide derivatives described in U.S. patent No. 3,923,784. However, prior art 5-O-desosaminylerythronolide derivatives are generally considered as inferior in the antibacterial properties, and actually, the above-mentioned derivatives have extremely weak antibacterial activity. An object of the present invention is to provide novel antibiotics having a strong antibacterial activity.

Disclosure of the Invention


As a result of various researches on the antibacterial activity of novel 5-O-desosaminylerythronolide derivatives, the present inventors have found that the compounds wherein a specific aryloxy group or an alkoxy group is introduced at the 3-position of 5-O-desosaminylerythronolide derivatives have unexpectedly an extremely strong antibacterial activity, and the present invention has been accomplished.

The present invention relates to a 5-O-desosaminylerythronolide derivative represented by the formula:

25


30

35



40 [wherein A is a group represented by the formula:


45



50 (wherein V is a hydroxyl group, W is a hydrogen atom or a hydroxyl group, or V and W together with the carbon atoms at the 11- and 12-positions form a cyclic carbonate group) or a group represented by the formula:

55

5



(wherein W' is a hydrogen atom or a hydroxyl group), B is a hydroxyl group or a methoxy group, U is a hydrogen atom or a C₂-C₈ alkanoyl group, Y is a C₄-C₆ cyclic alkyl group containing an oxygen atom, a phenyl group, a phenyl group substituted by one to 5 members selected from the group consisting of halogen atoms, nitro groups, trifluoromethyl groups and amino groups, a glucopyranosyl group, a glucopyranosyl group substituted by an acetyl group or a benzyl group, a hydroxyl group, a ribopyranosyl group substituted by an acetyl group or a benzyl group on the hydroxyl group, a benzyl group, a benzyl group substituted by a C₁-C₃ alkyl group; or methyl group, Z is an oxygen atom or a group represented by the formula: =N-O-R¹ (wherein R¹ is a hydrogen atom, a C₂-C₈ alkanoyl group, a benzyl group or a benzyl group substituted by one to 5 members selected from the group consisting of halogen atoms and C₁-C₄ alkyl groups)] or a pharmaceutically acceptable acid addition salt thereof.

10 In the present invention, the alkanoyl group refers to, for example, an acetyl group, a propionyl group or benzoyl group. The cyclic alkyl group containing an oxygen atom refers to, for example, a tetrahydropyranyl group or a tetrahydrofuryl group. The halogen atom refers to a fluorine atom, a chlorine atom, a bromine atom or an iodine atom. The alkyl group refers to a straight or branched chain alkyl group. The pharmaceutically acceptable acid addition salt refers to, for example, acetate, propionate, butyrate, formate, trifluoroacetate, maleate, tartrate, citrate, stearate, succinate, ethylsuccinate, lactobionate, gluconate, glucoheptonate, benzoate, methanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, benzenesulfonate, p-toluenesulfonate, laurylsulfate, malate, aspartate, glutamate, adipate, cysteine salt, hydrochloride, hydrobromide, phosphate, sulfate, hydroiodide, nicotinate, oxalate, picrate, thiocyanate, undecanoate, polyacrylate or carboxyvinyl polymer salt.

15 The compounds of the invention are those in which the configurations at the 3-position include both of a natural type (S-form) and a non-natural type (R-form).


20 The compounds of the present invention can be prepared, for example, as follows.

[Preparation Method 1] Method using 6-O-methylerythromycin A 9-oxime as a starting material

35

Step (1); 6-O-Methylerythromycin A 9-oxime is first reacted with an acid in an organic solvent at a temperature of from 0 °C to 30 °C to give a compound represented by the formula (a):

40




45

50

55


Examples of the organic solvent to be used herein are a lower alcohol (e.g. methanol, ethanol, propyl alcohol or butyl alcohol), and examples of the acid to be used are hydrochloric acid, hydrobromic acid and sulfuric acid. Preferable reaction temperature is room temperature.

Step (2); The compound (a) is reacted with an acid anhydride represented by the formula R^2_2O (wherein R^2 is an alkanoyl group or a benzoyl group) and a base in an inert solvent or an acid halide represented by the formula R^3-X (wherein R^3 is an alkanoyl group, a benzoyl group or a benzyloxycarbonyl group, and X is a halogen atom) and a base in an inert solvent at a temperature of from 0°C to 30°C to give a compound represented by the formula (b):




(wherein R' is the same as defined in R^2 or R^3). Examples of the inert solvent to be used herein are dichloromethane, dichloroethane, acetone and pyridine. The acid anhydride and acid halide to be used are those, for example, of acetic acid, propionic acid or benzoic acid. Examples of the base to be used are sodium bicarbonate, sodium carbonate, potassium carbonate, triethylamine, pyridine and tributylamine.

Step (3); The compound (b) is reacted with a glucopyranosyl group or a ribopyranosyl group, each of which is substituted by an acyl group, a halogen atom, an imidate group or a 3,5-dinitropyridyl group on the 1-hydroxyl group in an inert solvent in the presence of an acid catalyst at a temperature of from -30°C to 30°C according to the method described in the literature [Tetrahedron Letters, Vol. 28, No. 50, page 6281 (1987)] to give a compound of the present invention represented by the formula (c):



(wherein R' is as defined above, and R^4 is a glucopyranosyl group or a ribopyranosyl group, each of which is substituted by an acetyl group or a benzyl group on the hydroxyl group). Examples of the inert solvent to be used herein are dichloromethane, toluene, acetonitrile, ether and n-hexane, and examples of the acid catalyst to be used are boron trifluoride ether complex, copper trifluoromethanesulfonate, silver perchlorate, tin chloride and p-toluenesulfonic acid.

Step (4); Then, the compound (c) is reacted with a base in a lower alcohol or an aqueous lower alcohol at a temperature of from room temperature to 80°C to give a compound of the present invention represented by the formula (d):




(wherein R^4' is a glucopyranosyl group or a ribopyranosyl group). The lower alcohol to be used herein is the same as in Step (1), and the base to be used herein includes carbonates.

20

Step (5); Further, the compound (a) is reacted with an alkyl halide represented by the formula: R^5-X (wherein R^5 is a benzyl group or a benzyl group substituted by one to 5 members selected from the group consisting of halogen atoms and alkyl groups having 1 to 4 carbon atoms, and X is as defined above) and a base in an inert solvent at a temperature of from -20 °C to 30 °C to give a compound of the present invention represented by the formula (e):


25



(wherein R^5 is as defined above). Examples of the inert solvent to be used herein are N,N-dimethylformamide, tetrahydrofuran, dimethyl sulfoxide, dioxane and a mixture thereof. Examples of the base to be used are potassium hydroxide, sodium hydroxide, sodium hydride, butyl lithium and sodium carbonate. Step (6); The compound of the formula (e) is reacted in the same conditions as in Step (2) to give a compound of the formula (f):


50

55




(wherein R^5 and R' are as defined above).

Step (7); The compound (f) is reacted with an alkyl halide represented by the formula: R^6-X (wherein R^6 is a methyl group, a phenyl group, a benzyl group, a phenyl group substituted by one to 5 members selected from the group consisting of halogen atoms, nitro groups, trifluoromethyl groups and amino groups, or a benzyl group substituted by one to 5 members selected from the group consisting of halogen atoms, nitro groups, trifluoromethyl groups and amino groups, and X is as defined above) under the same conditions as in Step (5), followed by reaction under the same conditions as in Step (4) for removal of the protective group R' at the 2'-position to give a compound of the present invention represented by the formula (g):




(wherein R^5 and R^6 are as defined above). The compound (g) can be also obtained by further reacting the compound (e) in the same manner as in Step (5).

Step (8); The compound (e) is reacted with a cyclic vinyl ether containing an oxygen atom in an inert solvent in the presence of an acid catalyst at a temperature of from 0 °C to 30 °C to give a compound of the present invention represented by the formula (h):




(wherein R^5 is as defined above and R^7 is a cyclic alkyl group containing an oxygen atom). The inert solvent and the acid catalyst to be used herein are the same as in Step (3).

20 Step (9); Each of the compound (g) and the compound (h) is reduced in a lower alcohol in the presence of palladium as a catalyst to give a compound of the present invention represented by the formula (i):



(wherein R^8 is the same group as defined in R^6 or R^7).


40 Step (10); The compound (i) is deoximated by using sodium bisulfite, sodium nitrite or titanium trichloride in an aqueous lower alcohol at a temperature of from 0 °C to 80 °C to give a compound of the present invention represented by the formula (j):




(wherein R⁸ is as defined above).

[Preparation Method 2] Method using 2'-O,3'-N-bis(benzyloxycarbonyl)-N-demethyl-6-O-methylerythromycin A 9-[O-(2-chlorobenzyl)oxime] described in U.S. patent No. 4,680,386 as a starting material

Step (11); 2'-O,3'-N-Bis(benzyloxycarbonyl)-N-demethyl-6-O-methylerythromycin A 9-[O-(2-chlorobenzyl)oxime] is reacted in the same manner as in Step (1), and the resulting compound is subjected to 11,12-cyclic carbonation using a reagent such as phosgene dimer or phosgene trimer and a base such as pyridine in an inert solvent at a temperature of from -20°C to 5°C to give a compound represented by the formula (k):



Step (12); Then, the compound (k) is reacted in the same manner as in Step (5) to give a compound represented by the formula (l):




(wherein R⁹ is a methyl group or a phenyl group which may be optionally substituted by one to 5 members selected from the group consisting of halogen atoms, nitro groups, trifluoromethyl groups and amino groups).

Step (13): The compound (**1**) is reacted in the same manner as in Step (9) for reductive removal of the protective groups, and then subjected to 3'-N-methylation using formic acid or formalin to give a


EP 0 682 038 A1

compound of the present invention represented by the formula (m):



20 (wherein R⁹ is as defined above).


Step (14); The compound (m) is reacted in the same manner as in Step (10) to give a compound of the present invention represented by the formula (n):



40 (wherein R⁹ is as defined above).

[Preparation Method 3] Method using 5-O-desosaminyl-6-O-methylerythonolide A as a starting material


45 Step (15); 5-O-Desosaminyl-6-O-methylerythonolide A is reacted in the same manner as in Step (5) to give a compound of the present invention represented by the formula (o):



75


(wherein R⁹ is as defined above).

Step (16); 5-O-Desosaminyl-6-O-methylerythronolide A is reacted in the same manner as in Step (2), and subjected to 11,12-cyclic carbonation using a reagent such as phosgene dimer or phosgene trimer and a base such as pyridine in an inert solvent at a temperature of from -20 °C to 5 °C, followed by reaction in the same manner as in Step (4) to give a compound represented by the formula (p):



40

Step (17); The compound (p) is reacted in the same manner as in Step (5) to give a compound of the present invention represented by the formula (q):

(wherein R⁹ is as defined above).

[Preparation Method 4] The compound of the present invention can be also obtained by reacting erythromycin A 9-oxime as a starting material under the same conditions as in Preparation Method 1.

5 The compounds of the present invention can be administered orally or parenterally in the dosage form such as, for example, tablets, capsules, powders, troches, ointments, suspensions, suppositories and injections, all of which can be prepared by conventional preparation techniques.

Industrial Utilization

10 The compounds of the present invention have a strong antibacterial activity against erythromycin-sensitive bacteria and resistant bacteria. Therefore, the compounds of the present invention are useful as antibacterial agents for the treatment of infectious diseases caused by bacteria in human beings and animals (including farm animals).

15 Best Mode for Carrying out the Invention

The present invention is illustrated in more detail by the following examples.

Example 1

20 Preparation of 3-O-(2,4-dinitro)phenyl-5-O-desosaminyl-6-O-methylerythronolide A

To a solution of 1.178 g (2 mmoles) of 5-O-desosaminyl-6-O-methylerythronolide A in 10 ml of tetrahydrofuran were added 2.5 ml (20 mmoles) of 2,4-dinitrofluorobenzene and 240 mg (6 mmoles) of 60% sodium hydride under ice-cooling. The temperature was allowed to return to room temperature gradually, the mixture was stirred for 24 hours, and the reaction solution was extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent; chloroform : methanol : 25% aqueous ammonia = 95:5:0.5) to give 880 mg of the title compound as a yellow foam.

Mass (FAB) m/z ; 756 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.28(6H, s), 3.10(3H, s), 3.27(1H, s), 4.04(1H, d, J=7Hz), 4.10(1H, s), 4.77(1H, d, J=11Hz), 7.49, 7.53(1H), 8.43 ~ 8.50(1H), 8.66 ~ 8.69(1H) IR(KBr, cm⁻¹) ; 3436, 1732, 1692, 1607, 1540, 1344, 1282, 1174

35 Example 2

Preparation of 3-O-(2-nitro-4-trifluoromethyl)-phenyl-5-O-desosaminyl-6-O-methylerythronolide A

40 To a solution of 1.178 g (2 mmoles) of 5-O-desosaminyl-6-O-methylerythronolide A in 10 ml of tetrahydrofuran were added 1.40 ml (10 mmoles) of 4-fluoro-3-nitrobenzotrifluoride and 120 mg (3 mmoles) of 60% sodium hydride under ice-cooling. The temperature was allowed to return to room temperature gradually, the mixture was stirred for 5 hours and worked up in the same manner as in Example 1 to give 1.04 g of the title compound as a yellow foam.

45 Mass (FAB) m/z ; 779 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.31(6H, s), 3.10(3H, s), 3.26(1H, s), 4.07(1H, s), 4.74(1H, d, J=11Hz), 7.42, 7.47(1H), 7.78 ~ 7.85(1H), 8.03, 8.04(1H) IR(KBr, cm⁻¹) ; 3436, 1732, 1693, 1626, 1543, 1327, 1282, 1175

50 Example 3

Preparation of 3-O-(2-nitro)phenyl-5-O-desosaminyl-6-O-methylerythronolide A

55 1.178 g (2 mmoles) of 5-O-desosaminyl-6-O-methylerythronolide A was reacted with 2.1 ml (20 mmoles) of 2-nitrofluorobenzene, 280 mg (7 mmoles) of 60% sodium hydride and 15 ml of tetrahydrofuran in the same manner as in Example 1 to give 560 mg of the title compound as a yellow foam.

Mass (FAB) m/z ; 711 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.26(6H, s), 3.11(3H, s), 4.07(1H, s), 4.11(1H, d, J=7Hz), 4.68(1H,

d, J = 11Hz), 6.97 ~ 7.05(1H), 7.27 ~ 7.33(1H), 7.49 ~ 7.57(1H), 7.72 ~ 7.77(1H)
 IR(KBr, cm⁻¹) ; 3467, 1732, 1692, 1605, 1530, 1276, 1173

Example 4

5

Preparation of 3-O-(4-methyl-2-nitro)phenyl-5-O-desosaminyl-6-O-methylerythronolide A

1.178 g (2 mmoles) of 5-O-desosaminyl-6-O-methylerythronolide A was reacted with 3.10 g (20 mmoles) of 4-fluoro-3-nitrotoluene, 200 mg (5 mmoles) of 60% sodium hydride and 10 ml of tetrahydrofuran in the same manner as in Example 1 to give 460 mg of the title compound as a yellow foam.

Mass (FAB) m/z ; 725 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.28(6H, s), 2.34(3H, s), 3.10(3H, s), 3.25(1H, broad-s), 4.05(1H, s), 4.13(1H, d, J = 7Hz), 4.62(1H, d, J = 11Hz), 7.15, 7.20(1H), 7.29 ~ 7.35(1H), 7.54, 7.55(1H)
 IR(KBr, cm⁻¹) ; 3459, 1731, 1692, 1533, 1258, 1173

15

Example 5

Preparation of 3-O-(4-fluoro-2-nitro)phenyl-5-O-desosaminyl-6-O-methylerythronolide A

20 One gram (1.698 mmoles) of 5-O-desosaminyl-6-O-methylerythronolide A was reacted with 0.92 ml (8.49 mmoles) of 2,5-difluoronitrobenzene, 152 mg (3.80 mmoles) of 60% sodium hydride and 10 ml of tetrahydrofuran in the same manner as in Example 1 to give 387 mg of the title compound as a yellow foam.

Mass (FAB) m/z ; 729 [MH]⁺

25 ¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.38(6H, s), 3.10(3H, s), 3.26(1H, s), 4.05(1H, s), 4.13(1H, d, J = 7Hz), 4.60(1H, d, J = 11Hz), 7.17 ~ 7.31(2H), 7.49 ~ 7.56(1H)
 IR(KBr, cm⁻¹) ; 3467, 1732, 1692, 1538, 1265, 1174

Example 6

30

Preparation of 3-O-(4,5-difluoro-2-nitro)phenyl-5-O-desosaminyl-6-O-methylerythronolide A

One gram (1.698 mmoles) of 5-O-desosaminyl-6-O-methylerythronolide A was reacted with 0.98 ml (8.49 mmoles) of 2,4,5-trifluoronitrobenzene, 102 mg (2.547 mmoles) of 60% sodium hydride and 10 ml of tetrahydrofuran in the same manner as in Example 1 to give 87 mg of the title compound as a yellow powder.

Mass (FAB) m/z ; 747 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.28(6H, s), 3.09(3H, s), 4.06(1H, d, J = 7Hz), 4.50(1H, d, J = 11Hz), 7.12 ~ 7.23(1H), 7.73 ~ 7.83(1H)
 40 IR(KBr, cm⁻¹) ; 3460, 1732, 1693, 1540, 1333, 1174

Example 7

45

Preparation of 3-O-(2,3-difluoro-6-nitro)phenyl-5-O-desosaminyl-6-O-methylerythronolide A

One gram (1.698 mmoles) of 5-O-desosaminyl-6-O-methylerythronolide A was reacted with 0.99 ml (8.49 mmoles) of 2,3,4-trifluoronitrobenzene, 102 mg (2.547 mmoles) of 60% sodium hydride and 10 ml of tetrahydrofuran in the same manner as in Example 1 to give 820 mg of the title compound as a yellow foam.

50 Mass (FAB) m/z ; 747 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.26(6H, s), 3.07(3H, s), 3.25(1H, broad-s), 4.00(1H, s), 4.19(1H, d, J = 7Hz), 5.00(1H, d, J = 11Hz), 6.85 ~ 6.98(1H), 7.53 ~ 7.63(1H)
 IR(KBr, cm⁻¹) ; 3467, 1734, 1540, 1467, 1173

55

EP 0 682 038 A1

Example 8

Preparation of 3-O-(2-amino)phenyl-5-O-desosaminyl-6-O-methylerythonolide A

To a solution of 500 mg (0.704 mmole) of the compound obtained in Example 3 in 5 ml of methanol were added 335 mg (1.41 mmoles) of nickel chloride hexahydrate and 107 mg (2.816 mmoles) of sodium borohydride under ice-cooling. After stirring for 1.5 hours, the reaction solution was poured into aqueous ammonia, followed by extraction with ethyl acetate. Purification in the same manner as in Example 1 gave 230 mg of the title compound as a pale brown foam.

Mass (FAB) m/z ; 681 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.25(6H, s), 3.10(3H, s), 4.00(1H, s), 4.55(1H, d, J = 11Hz), 6.65 – 7.03(4H)

IR(KBr, cm⁻¹) ; 3452, 1732, 1692, 1504, 1459, 1172

Example 9

Preparation of 3-O-(2,4-dinitro)phenyl-5-O-desosaminyl-6-O-methylerythonolide A 11,12-cyclic carbonate

To a solution of 11.78 g (0.02 mole) of 5-O-desosaminyl-6-O-methylerythonolide A in 100 ml of acetone was added 2.27 ml (0.024 mole) of acetic anhydride under ice-cooling, followed by stirring at room temperature for 6 hours. The acetone was evaporated under reduced pressure, and the residue was extracted with dichloromethane. The dichloromethane layer was washed with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution successively, and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was recrystallized from ether-n-hexane to give 12.17 g of 2'-O-acetyl-5-O-desosaminyl-6-O-methylerythonolide A as a white powder.

mp : 158 – 160 °C

Mass (FAB) m/z ; 632 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.07(3H, s), 2.26(6H, s), 2.95(3H, s), 3.26(1H, s), 3.96(1H, s)

IR(KBr, cm⁻¹) ; 3469, 1750, 1733, 1693

To a solution of 50 g (84.8 mmole) of the compound obtained in the above (1) in 500 ml of dichloromethane was added 102.6 ml (1.27 moles) of pyridine under ice-cooling, and then a solution of 25.4 ml (212 mmole) of trichloromethyl chloroformate in 40 ml of dichloromethane was added dropwise thereto at the same temperature, followed by stirring for 5.5 hours. Cooled water and a saturated aqueous sodium bicarbonate solution were added gradually to the reaction solution, followed by extraction with dichloromethane. The dichloromethane layer was washed with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution successively, and dried over anhydrous magnesium sulfate. After evaporation of the solvent under reduced pressure, the residue was purified by silica gel column chromatography (eluent; acetone : n-hexane : triethylamine = 6 to 10:10:0.2) to give 41.93 g of 2'-O-acetyl-5-O-desosaminyl-6-O-methylerythonolide A 11,12-cyclic carbonate as a white foam.

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.05(3H, s), 2.25(6H, s), 2.92(3H, s), 4.57(1H, d, J = 9Hz), 4.74(1H, s), 4.75(1H, dd, J = 10Hz, 9Hz), 5.13(1H, dd, J = 12Hz, 2Hz)

800 mg (1.218 mmole) of the compound obtained in the above (2) in 5 ml of methanol was heated under reflux for 5 hours. After evaporation of the methanol, the residue was extracted with ethyl acetate. The ethyl acetate layer was washed with a saturated aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate. After evaporation of the solvent under reduced pressure, the residue was recrystallized from methanol to give 603 mg of 5-O-desosaminyl-6-O-methylerythonolide A 11,12-cyclic carbonate as a white powder.

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 1.51(3H, s), 2.50(6H, s), 2.94(3H, s), 4.51(1H, d, J = 7Hz), 4.76(1H, s), 5.14(1H, dd, J = 11Hz, 3Hz)

440 mg (0.715 mmole) of the compound obtained in the above (3) was reacted with 0.6 ml (4.769 mmole) of 2,4-dinitrofluorobenzene, 86 mg (2.145 mmole) of 60% sodium hydride and 3 ml of tetrahydrofuran in the same manner as in Example 1 to give 300 mg of the title compound as a yellow powder.

Mass (FAB) m/z ; 782 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 1.52(3H, s), 2.42(6H, s), 3.06(3H, s), 4.06(1H, d, J = 7Hz), 4.70(1H, s), 4.80(1H, d, J = 11Hz), 7.53, 7.60(1H), 8.45 – 8.53(1H), 8.68, 8.70(1H)

IR(KBr, cm⁻¹) ; 3436, 1809, 1737, 1713, 1606, 1537, 1344, 1317, 1281

Example 10

- 5 Preparation of 3-O-(2-methyl)benzyl-5-O-desosaminyl-6-O-methylerythronolide A 9-[O-(2-chlorobenzyl)-oxime]

(1) To 500 g (0.655 mole) of 6-O-methylerythromycin A 9-oxime was added 1 L of 1N hydrochloric acid, followed by allowing to stand at room temperature for 24 hours. The mixture was adjusted to pH 10 by adding sodium hydroxide solution, and the precipitated crystals were collected by filtration. The crystals were dissolved in dichloromethane, washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate. The dichloromethane was evaporated under reduced pressure, and the residue was crystallized from methanol to give 259.8 g of 5-O-desosaminyl-6-O-methylerythronolide A 9-oxime as white crystals.

15 mp ; 257 ~ 260 °C

Mass (FAB) m/z ; 605 [MH]⁺

¹H-NMR (300MHz, CDCl₃) δ (ppm) ; 1.42(3H, s), 2.34(6H, s), 2.99(3H, s), 3.26(1H, s), 3.57(1H, s), 4.37(1H, s), 4.42(1H, d, J = 7Hz), 5.23(1H, dd, J = 11Hz, 2Hz), 7.43(1H, broad-s)

IR(KBr, cm⁻¹) ; 3523, 3370, 1712, 1188, 1169, 1085

20 Alternatively, 5-O-desosaminyl-6-O-methylerythronolide A 9-oxime was also obtained by oximation of 5-O-desosaminyl-6-O-methylerythronolide A in methanol using hydroxylamine hydrochloride and imidazole.

(2) To a solution of 3.02 g (5 mmoles) of the compound obtained in the above (1) in 30 ml of N,N-dimethylformamide were added 0.94 ml (7.50 mmoles) of 2-chlorobenzyl chloride and 240 mg (6 mmoles) of 60% sodium hydride under ice-cooling. After stirring for 5 hours, the mixture was extracted and purified in the same manners as in Example 1 to give 1.91 g of 5-O-desosaminyl-6-O-methylerythronolide A 9-[O-(2-chlorobenzyl)oxime] as a white foam.

(3) 2.148 g (2.947 mmoles) of the compound obtained in the above (2), 1.17 ml (8.841 mmoles) of 2-methylbenzyl chloride, 525 mg (8.841 mmoles) of 96% potassium hydroxide powder and 20 ml of tetrahydrofuran were reacted in the same manner as in Example 1 to give 613 mg of the title compound as a white foam.

Mass (FAB) m/z ; 833 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.17(6H, s), 2.38(3H, s), 2.93(3H, s), 3.26(1H, s), 4.21(1H, d, J = 7Hz), 4.40(1H, s), 4.03, 4.93(2H, ABq, J = 14Hz), 5.13, 5.17(2H), 7.10 ~ 7.67(8H)

35 IR(KBr, cm⁻¹) ; 3447, 1732, 1457, 1170, 1083

Example 11

Preparation of 5-O-desosaminyl-3,6-di-O-methylerythronolide A 9-oxime 11,12-cyclic carbonate

40 (1) 5.0 g (4.38 mmoles) of 2'-O,3'-N-bis(benzyloxycarbonyl)-N-demethyl-6-O-methylerythromycin A 9-[O-(2-chlorobenzyl)oxime] was reacted in the same manner as in Example 10(1) to give 2.99 g of 2'-O,3'-N-bis(benzyloxycarbonyl)-N-demethyl-5-O-desosaminyl-6-O-methylerythronolide A 9-[O-(2-chlorobenzyl)-oxime].

45 (2) 3.01 g (3.06 mmoles) of the compound obtained in the above (1) was reacted with 1.1 ml (9.18 mmoles) of trichloromethyl chloroformate and 4.94 ml (61.2 mmoles) of pyridine in 55 ml of dichloromethane in the same manner as in Example 9(2) to give 930 mg of 2'-O,3'-N-bis(benzyloxycarbonyl)-N-demethyl-5-O-desosaminyl-6-O-methylerythronolide A 9-[O-(2-chlorobenzyl)oxime] 11,12-cyclic carbonate as a white foam.

50 (3) To a solution of 920 mg (0.912 mmole) of the compound obtained in the above (2) in a mixture of 7 ml of dimethyl sulfoxide and 7 ml of tetrahydrofuran were added 0.57 ml (9.12 mmoles) of methyl iodide and 110 mg (1.879 mmoles) of 96% potassium hydroxide powder under ice-cooling. The temperature was allowed to return to room temperature gradually, and the mixture was stirred for 5.5 hours. The reaction solution, after addition of 2 ml of triethylamine, was extracted with ethyl acetate, and worked up in a conventional manner. The residue was purified by silica gel column chromatography (eluent; ethyl acetate : n-hexane = 1:3) to give 790 mg of 2'-O,3'-N-bis(benzyloxycarbonyl)-N-demethyl-5-O-desosaminyl-3,6-di-O-methylerythronolide A 9-[O-(2-chlorobenzyl)oxime] 11,12-cyclic carbonate as a white foam.

EP 0 682 038 A1

(4) 780 mg (0.762 mmole) of the compound obtained in the above (3), 300 mg of 10% palladium carbon, 0.46 ml (12.192 mmoles) of formic acid and 96 mg (1.524 mmoles) of ammonium formate in 40 ml of methanol were together heated under reflux for 4 hours. After addition of 35% aqueous formalin solution, the mixture was heated under reflux for 3 hours, and the catalyst was removed by filtration. The methanol was evaporated under reduced pressure, and the residue was made basic with a saturated aqueous sodium carbonate solution and extracted with ethyl acetate. After working up in a conventional manner, purification by silica gel column chromatography (eluent; chloroform : methanol : 25% aqueous ammonia = 20:1:0.1) gave 326 mg of the title compound as a white foam.

Mass (FAB) m/z ; 645 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.42(6H, s), 3.01(3H, s), 3.57(3H, s), 4.43(1H, d, J = 8Hz), 4.86-(1H, s), 8.35(1H, broad-s)

Example 12

15 Preparation of 3-O-(2-tetrahydropyranyl)-5-O-desosaminyl-6-O-methylerythonolide A

(1) 2 g (2.93 mmole) of 5-O-desosaminyl-6-O-methylerythonolide A 9-[O-(benzyl)oxime] obtained by the same reaction as in Example 10(2) using the compound obtained in Example 10(1) and benzyl chloride was dissolved in 20 ml of dichloromethane, and then 4 g of Molecular Sieves 4A, 0.84 ml (9.21 mmole) of dihydropyran and 892 mg (4.69 mmole) of p-toluenesulfonic acid monohydrate were added thereto, followed by stirring at room temperature for 7 hours. The reaction solution was extracted with dichloromethane and worked up in a conventional manner. The residue was purified by silica gel column chromatography (eluent; acetone : n-hexane : triethylamine = 3:10:0.2) to give 0.24 g of 3-O-(2-tetrahydropyranyl)-5-O-desosaminyl-6-O-methylerythonolide A 9-[O-(benzyl)oxime].

20 (2) To a solution of 0.3 g (0.39 mmole) of the compound obtained in the above (1) in 3 ml of methanol were added 100 mg of 10% palladium carbon, 40 mg (0.63 mmole) of ammonium formate and 0.12 ml (3.13 mmole) of 99% formic acid, followed by reaction at 50 °C for 30 minutes. After removal of the catalyst by filtration, evaporation of the solvent under reduced pressure gave 244 mg of 3-O-(2-tetrahydropyranyl)-5-O-desosaminyl-6-O-methylerythonolide A 9-oxime.

25 (3) To a solution of 220 mg (0.32 mmole) of the compound obtained in the above (2) in a mixture of 1 ml of ethanol and 1.5 ml of water were added 432 mg (4.15 mmole) of sodium bisulfite and 0.02 ml (0.52 mmole) of 99% formic acid, followed by heating under reflux for 30 minutes. The mixture was made basic with 2N sodium hydroxide solution and extracted with ethyl acetate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent; chloroform : methanol : 25% aqueous ammonia = 20:1:0.1) to give 130 mg of the title compound.

30 Mass (FAB) m/z ; 674 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.31(6H, s), 2.98(3H, s), 4.00(1H, m)

40 Example 13

Preparation of 10,11-anhydro-5-O-desosaminyl-3,6-di-O-methylerythonolide A

45 280 mg (0.434 mmole) of the compound obtained in Example 11, 316 mg (3.038 mmoles) of sodium bisulfite, 5 ml of ethanol and 5 ml of water were together heated under reflux for 4 hours. Working up in the same manner as in Example 12(3) gave 66 mg of the title compound as a white foam.

Mass (FAB) m/z ; 586 [MH]⁺

50 ¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.01(3H, s), 2.31(6H, s), 3.16(3H, s), 3.56(3H, s), 4.38(1H, d, J = 7Hz), 6.45(1H, s)

Example 14

Preparation of 5-O-desosaminyl-3,6-di-O-methylerythonolide A 9-[O-(2-chlorobenzyl)oxime]

55 (1) To a solution of 2.148 g (2.946 mmole) of the compound obtained in Example 10(2) in 20 ml of dichloromethane were added 1.26 g (14.73 mmole) of sodium bisulfite and 0.85 ml (5.892 mmole) of benzyloxycarbonyl chloride under ice-cooling. The temperature was allowed to return to room temperature gradually, and the mixture was stirred at room temperature for 24 hours. The reaction solution was

extracted with dichloromethane, and worked up in a conventional manner. The residue was purified by silica gel column chromatography (eluent; chloroform : acetone = 2:1) to give 1.76 g of 2'-O-benzylloxycarbonyl-5-O-desosaminyl-6-O-methylerythronolide A 9-[O-(2-chlorobenzyl)oxime] as a white foam.

(2) 1.76 g (2.039 mmoles) of the compound obtained in the above (1) was reacted with 0.38 ml (6.117 mmoles) of methyl iodide and 357 mg (6.117 mmoles) of 96% potassium hydroxide powder in a mixture of 10 ml of dimethyl sulfoxide and 10 ml of tetrahydrofuran in the same manner as in Example 11(3) to give 550 mg of 2'-O-benzylloxycarbonyl-5-O-desosaminyl-3,6-di-O-methylerythronolide A 9-[O-(2-chlorobenzyl)oxime] as a white foam.

(3) 150 mg (0.171 mmole) of the compound obtained in the above (2), 70 mg (0.833 mmole) of sodium bicarbonate, 13 ml of methanol and 5 ml of water were together stirred at 55°C for 4 hours. The methanol was evaporated under reduced pressure, and the residue was extracted with ethyl acetate and worked up in a conventional manner to give 136 mg of the title compound as a white foam.

Mass (FAB) m/z ; 743 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.32(6H, s), 2.90(3H, s), 3.56(3H, s), 4.79(2H, s), 7.15 ~ 7.49 (4H)

Example 15

Preparation of 3-O-(β-D-glucopyranosyl)-5-O-desosaminyl-6-O-methylerythronolide A 9-oxime

(1) 10 g (25.6 mmoles) of α-D-glucose pentaacetate and 2 g (21.7 mmoles) of hydrazine acetate in N,N-dimethylformamide were together stirred at 50°C for 45 minutes. The reaction solution was extracted with ethyl acetate, and washed with a saturated aqueous sodium chloride solution. After working up in a conventional manner, purification by silica gel column chromatography (eluent; ether : n-hexane = 2:1 to 3:1) gave 5.45 g of 2,3,4,6-tetra-O-acetyl-α-D-glucose.

(2) To a solution of 5.45 g (15.66 mmoles) of the compound obtained in the above (1) in 15 ml of dichloromethane were added 5.45 ml (53.95 mmoles) of trichloroacetonitrile and 623 mg (15.58 mmoles) of 60% sodium hydride under ice-cooling, followed by stirring for 4 hours. The reaction solution was extracted with dichloromethane, and worked up in a conventional manner. The residue was purified by silica gel column chromatography (eluent; ether : n-hexane = 3:1) to give 3.91 g of O-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-trichloroacetoimidate.

(3) To a solution of 6 g (9.936 mmoles) of the compound obtained in Example 10(1) in 240 ml of dichloromethane were added 2.32 ml (24.84 mmoles) of acetic anhydride and 4.16 g (49.68 mmoles) of sodium bicarbonate under ice-cooling. The temperature was allowed to return to room temperature gradually, and the mixture was stirred for 6.5 hours. The reaction solution was extracted with dichloromethane and worked up in a conventional manner to give 7.18 g of 2'-O-acetyl-5-O-desosaminyl-6-O-methylerythronolide A 9-acetoxime.

(4) To a solution of 1.36 g (2 mmoles) of the compound obtained in the above (3) in 15 ml of tetrahydrofuran were added 4 g of Molecular Sieves 4A, 0.3 ml (2.4 mmoles) of boron trifluoride ethyl ether complex and 1.33 g (2.7 mmoles) of the compound obtained in the above (2) under ice-cooling, followed by stirring for 7 hours. The molecular sieves were removed by filtration, the reaction solution was made basic with a saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. Working up in a conventional manner gave 680 mg of 3-O-tetraacetylglucosyl-5-O-desosaminyl-6-O-methylerythronolide A 9-acetoxime.

(5) 670 mg (6.58 mmoles) of the compound obtained in the above (4) and 0.66 ml (3.19 mmoles) of 28% sodium methoxide methanol solution were together stirred in 12 ml of methanol for 2 days. The methanol was evaporated under reduced pressure, and the residue was made basic with aqueous ammonia and extracted with ethyl acetate. After working up in a conventional manner, purification by silica gel column chromatography (eluent; chloroform : methanol = 1:1) gave 130 mg of the title compound.

Mass (FAB) m/z ; 767 [MH]⁺

¹H-NMR (200MHz, CDCl₃) δ (ppm) ; 2.35(6H, s), 3.03(3H, s), 4.01(1H, s), 4.41(1H), 4.69(1H), 5.64(1H)

Example 16

Preparation of 2'-O-acetyl-3-O-[β -D-(2,3,4-triacetyl)ribopyranosyl]-5-O-desosaminyl-6-O-methylerythonolide A 9-acetoxime

5 688 mg (1 mmole) of 2'-O-acetyl-5-O-desosaminyl-6-O-methylerythonolide A 9-acetoxime and 470 mg (1.12 mmoles) of a compound obtained by treating β -D-ribopyranose 1,2,3,4-tetraacetate in the same manners as in Example 15(1) and (2), were reacted in the same manner as in Example 15(4) to give 120 mg of the title compound.

10 $^1\text{H-NMR}$ (200MHz, CDCl_3) δ (ppm) ; 2.05(3H, s), 2.06(6H, s), 2.15(3H, s), 2.17(3H, s), 2.29(6H, s), 2.95-3H, s), 4.41(1H, d, $J=8\text{Hz}$)

Experiment (In Vitro Antibacterial Activity)

15 The in vitro antibacterial activity of the compound of the present invention obtained in Example 9 against various experimental bacteria was measured using sensitive disc media (produced by Eiken Chemical Co.) according to the MIC measuring method specified by the Japan Society of Chemotherapy. 6-O-Methylerythromycin A was used as a comparative drug. The results are expressed as MIC value (Minimum Inhibitory Concentration, mcg/ml), and shown in Table 1.

20

Table 1


In vitro antibacterial activity		MIC value (mcg/ml)	
Microorganism	Compound	Example 9	Comparative drug
<u>S. aureus</u> 209P-JC		0.10	0.10
<u>S. aureus</u> Smith 4		0.10	0.10
<u>S. epidermidis</u> IID 866		0.10	0.10
<u>E. faecalis</u> CSJ 1212		0.20	0.78
<u>S. aureus</u> B1		0.78	>100

40

Claims

1. A 5-O-desosaminylerythonolide derivative represented by the formula:


45



50


[wherein A is a group represented by the formula:

5



(wherein V is a hydroxyl group, W is a hydrogen atom or a hydroxyl group, or V and W together with the carbon atoms at the 11- and 12-positions form a cyclic carbonate group) or a group represented by the formula:

15



20

(wherein W' is a hydrogen atom or a hydroxyl group), B is a hydroxyl group or a methoxy group, U is a hydrogen atom or a C₂-C₈ alkanoyl group, Y is a C₄-C₆ cyclic alkyl group containing an oxygen atom, a phenyl group, a phenyl group substituted by one to 5 members selected from the group consisting of halogen atoms, nitro groups, trifluoromethyl groups and amino groups, a glucopyranosyl group, a ribopyranosyl group, a glucopyranosyl group substituted by an acetyl group or a benzyl group on the hydroxyl group, a ribopyranosyl group substituted by an acetyl group or a benzyl group on the hydroxyl group, a benzyl group, a benzyl group substituted by a C₁-C₃ alkyl group; or methyl group, Z is an oxygen atom or a group represented by the formula: =N-O-R¹ (wherein R¹ is a hydrogen atom, a C₂-C₈ alkanoyl group, a benzyl group or a benzyl group substituted by one to 5 members selected from the group consisting of halogen atoms and C₁-C₄ alkyl groups)] or a pharmaceutically acceptable acid addition salt thereof.

35

40

45

50

55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP94/00087

A. CLASSIFICATION OF SUBJECT MATTER

Int. C15 C07H17/08 // A61K31/71

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. C15 C07H17/08

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, A, 4-290893 (Roussl Huchaf), October 15, 1992 (15. 10. 92) & EP, A1, 487411 & AU, A, 9187986 & FR, A1, 2669337 & BR, A, 9105062 & FR, A1, 2677025 & FR, A1, 2680790	1
P	WO, A1, 93-13116 (Taisho Pharmaceutical Co., Ltd.), July 8, 1993 (08. 07. 93) & AU, A, 9331728	1

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search April 5, 1994 (05. 04. 94)	Date of mailing of the international search report April 26, 1994 (26. 04. 94)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.	Authorized officer Telephone No.